| Literature DB >> 33206936 |
Jenny Klintman1,2,3, Niamh Appleby1,2,4, Basile Stamatopoulos1,5, Katie Ridout1,2, Toby A Eyre4, Pauline Robbe1,2, Laura Lopez Pascua1,2, Samantha J L Knight6,7, Helene Dreau1,2, Maite Cabes4, Niko Popitsch6,7,8, Mats Ehinger9, Jose I Martín-Subero10,11, Elías Campo10, Robert Månsson12,13, Davide Rossi14, Jenny C Taylor6,7, Dimitrios V Vavoulis1,2,6,7, Anna Schuh1,2,4,6.
Abstract
The transformation of chronic lymphocytic leukemia (CLL) to high-grade B-cell lymphoma is known as Richter syndrome (RS), a rare event with dismal prognosis. In this study, we conducted whole-genome sequencing (WGS) of paired circulating CLL (PB-CLL) and RS biopsies (tissue-RS) from 17 patients recruited into a clinical trial (CHOP-O). We found that tissue-RS was enriched for mutations in poor-risk CLL drivers and genes in the DNA damage response (DDR) pathway. In addition, we identified genomic aberrations not previously implicated in RS, including the protein tyrosine phosphatase receptor (PTPRD) and tumor necrosis factor receptor-associated factor 3 (TRAF3). In the noncoding genome, we discovered activation-induced cytidine deaminase-related and unrelated kataegis in tissue-RS affecting regulatory regions of key immune-regulatory genes. These include BTG2, CXCR4, NFATC1, PAX5, NOTCH-1, SLC44A5, FCRL3, SELL, TNIP2, and TRIM13. Furthermore, differences between the global mutation signatures of pairs of PB-CLL and tissue-RS samples implicate DDR as the dominant mechanism driving transformation. Pathway-based clonal deconvolution analysis showed that genes in the MAPK and DDR pathways demonstrate high clonal-expansion probability. Direct comparison of nodal-CLL and tissue-RS pairs from an independent cohort confirmed differential expression of the same pathways by RNA expression profiling. Our integrated analysis of WGS and RNA expression data significantly extends previous targeted approaches, which were limited by the lack of germline samples, and it facilitates the identification of novel genomic correlates implicated in RS transformation, which could be targeted therapeutically. Our results inform the future selection of investigative agents for a UK clinical platform study. This trial was registered at www.clinicaltrials.gov as #NCT03899337.Entities:
Mesh:
Substances:
Year: 2021 PMID: 33206936 PMCID: PMC8163497 DOI: 10.1182/blood.2020005650
Source DB: PubMed Journal: Blood ISSN: 0006-4971 Impact factor: 22.113